Skip to main content
SpringerLink
Log in

The Commercialization of Clinical Genetics: An Analysis of Interrelations Between Academic Centers and For-Profit Clinical Genetics Diagnostics Companies

  • Published:
Journal of Genetic Counseling

Abstract

The field of clinical genetics has undergone substantial commercialization, including the development of genetics diagnostics companies. Numerous for-profit corporations now offer genetic diagnostic services; until recently, these clinical services were provided almost exclusively through academic, not-for-profit medical centers. Some of these for-profit corporations have business and/or research relationships with academia. An evaluation of the interconnections between academia and the clinical genetics industry is an important first step in analyzing the risks and benefits of commercialization. We analyzed the personnel and business affiliations of 19 major U.S. for-profit clinical genetics diagnostics companies with universities, academic medical centers, and the scientific and medical genetics communities in a 2-year period, 1991–1992. We noted extensive connections between the for-profit sector and academia. At least 17% of high-ranking personnel and 85% of consultants for the companies had one or more academic ties. At least 68% of the companies had one or more business agreements with at least one university or academic medical center. These results raise many issues regarding the delivery of genetic medicine and the structure and function of academic medical genetics centers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Anderson C (1992) Conflict concerns disrupt panels, cloud testimony. Nature 355:753–754.

    Google Scholar 

  • Anderson C (1993) Genome project goes commercial. Science 259:300–302.

    Google Scholar 

  • Benn P, Ciarleglio L, Lettieri L, Rodis J, Greenstein R (1992) A rapid (but wrong) prenatal diagnosis. N Engl J Med 326:1638–1639.

    Google Scholar 

  • Billings PR, Lippman A, Wilker N (1992) Conflicts, ethics, and the genome. Am J Hum Genet 51:1168.

    Google Scholar 

  • Blumenthal D, Gluck M, Louis KS, Wise D (1986a) Industrial support of university research in biotechnology. Science 231:242–246.

    Google Scholar 

  • Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D (1986b) University-industry research relationships in biotechnology: Implications for the university. Science 232:1361–1366.

    Google Scholar 

  • Blumenthal D (1992) Academic-industry relationships in the life sciences: Extent, consequences, and management. J Am Med Assoc 268:3344–3349.

    Google Scholar 

  • Blumenthal D, Causino N, Campbell E, Louis KS (1996) Relationships between academic institutions and industry in the life sciences—an industry survey. N Engl J Med 334:368–373.

    Google Scholar 

  • Bylinsky G (1994) Genetics: The money rush is on. Fortune 129:94–108.

    Google Scholar 

  • Collins F, Galas D (1993) A new five-year plan for the U.S. Human Genome Project. Science 262:43–46.

    Google Scholar 

  • Culotta E (1993) New start-ups move in as gene therapy goes commercial. Science 260:914–915.

    Google Scholar 

  • Dickinson D (1995) UK calls for regulation of genetic testing. Nature Med 1:855–856.

    Google Scholar 

  • Dustira AK (1992) The funding of basic and clinical biomedical research. In: Porter RJ, Malone TE (eds) Biomedical Research: Collaboration and Conflict of Interest. New York: Johns Hopkins University Press, pp 33–56.

    Google Scholar 

  • Eisenberg RS (1988) Academic freedom and academic values in sponsored research. Texas Law Rev 66:1363–1409.

    Google Scholar 

  • Feldbaum CB (1993) The year behind-the challenges ahead. In: Burril GS, Lee KB Jr (eds) Biotech 94 Long-Term Values Short Term Hurdles. San Francisco: Ernst & Young, p 1.

    Google Scholar 

  • Fisher LM (1994) Profits and ethics clash in research on genetic coding. New York Times January 30, pp 1, 18.

  • Fox JL (1994) Bio's effective lobbying efforts. Bio/Technol 12:567–568.

    Google Scholar 

  • Geiger RL (1993) Research and Relevant Knowledge: American Research Universities Since World War II. New York: Oxford University Press, pp 296–309.

    Google Scholar 

  • Gershon D (1996) Counselling comes of age. Nature 383:741–742.

    Google Scholar 

  • Hagerman RJ, Wilson P, Staley LW, et al. (1994) Evaluation of school children at high risk for Fragile X syndrome utilizing buccal cell FMR-1 testing. Am J Med Genet 51:474–481.

    Google Scholar 

  • Harper PS (1995) Direct marketing of cystic fibrosis carrier screening: Commerical push or population need? J Med Genet 32:249–250.

    Google Scholar 

  • Hecht F, Hecht BK (1992) Descent into demonology and protectionism. Am J Hum Genet 51:893–894.

    Google Scholar 

  • Henderson R (1994) Managing innovation in the information age. Harvard Bus Rev 72:100–105.

    Google Scholar 

  • Hood L (1992) Biology and medicine in the twenty-first century. In: Kevles DJ, Hood L (eds) The Code of Codes: Scientific and Social Issues in the Human Genome Project. Cambridge: Harvard University Press, pp 136–163.

    Google Scholar 

  • Kenney M (1986) Biotechnology: The University-Industrial Complex. New Haven: Yale University Press, pp 1–306.

    Google Scholar 

  • Knox RA (1994) Drug makers' aggressive marketing questioned. Boston Globe, May 11, pp 1, 14.

  • Kolata G (1994) Selling growth drug for children: The legal and ethical questions. New York Times August 15, pp A1, A13.

  • Krimsky S (1991) Biotechnics and Society: The Rise of Industrial Genetics. New York: Praeger, pp 1–263.

    Google Scholar 

  • Krimsky S, Ennis JG, Weissman R (1991) Academic-corporate ties in biotechnology: A quantitative study. Sci Technol Hum Val 16:275–287.

    Google Scholar 

  • Kuliopulos H (1996) Summary. Managed Care and Genetics: Translating Needs into Action, A PSRGN Conference. Genetically Speaking 7:No. 1 (Suppl.) pp 1–6, Pacific Southwest Regional Genetics Network.

    Google Scholar 

  • Laster L (1995) Let the patient beware. Boston Globe November 5, pp 81, 85.

  • Leopold M (1993) The commercialization of biotechnology: The shifting frontier. In: Tzotzos GT (ed) Biotechnology R&D Trends: Science Policy for Development. New York: New York Academy of Sciences, pp 214–231.

    Google Scholar 

  • Marshall E (1990) When commerce and academe collide. Science 248:152–156.

    Google Scholar 

  • Milunsky A (1992a) Threatened survival of academic-based genetic laboratory services. Am J Hum Genet 50:643–645.

    Google Scholar 

  • Milunsky A (1992b) Reply to Hecht and Hecht, Trigg and Geier, and Warren. Am J Hum Genet 51:894–895.

    Google Scholar 

  • Milunsky A (1993) Commercialization of clinical genetic laboratory services: In whose best interest? Ob Gyn 81: 627–629.

    Google Scholar 

  • National Academy of Sciences. Government-Industry Research Roundtable (1992) Fateful Choices: The Future of the U.S. Academic Research Enterprise. Washington, DC: Natl. Acad. Press, pp 12–18.

    Google Scholar 

  • National Academy of Sciences. Government-Industry Research Roundtable (1994) Stresses on Research and Education at Colleges and Universities: Institutional and Sponsoring Agency Responses. Washington, DC: National Academy Press, pp 1–15.

    Google Scholar 

  • Noble RC (1993) Physicians and the pharmaceutical industry: An alliance with unhealthy aspects. Perspect Biol Med 36:376–394.

    Google Scholar 

  • Nowak R (1994) Genetic testing set for takeoff. Science 265:464–467.

    Google Scholar 

  • Office of Technology Assessment (1992a) Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease. Washington, DC: U.S. Govt. Printing Office.

    Google Scholar 

  • Office of Technology Assessment (1992b) Genetic Counseling and Cystic Fibrosis Carrier Screening: Results of a Survey. Washington, DC: U.S. Govt. Printing Office, pp 1–60.

    Google Scholar 

  • Relman AS (1980) The new medical-industrial complex. N Engl J Med 303:963–970.

    Google Scholar 

  • Relman AS (1989) Economic incentives in clinical investigations. N Engl J Med 320:933–934.

    Google Scholar 

  • Relman AS (1995) Profit and commercialism. In: Reich WT (ed) Encyclopedia of Bioethics. New York: Macmilian, pp 1063–1066.

    Google Scholar 

  • Rosenberg R (1992) A cure at any price. Boston Globe March 15, pp 75, 79.

  • Rosner F (1992) Ethical relationships between drug companies and the medical profession. Chest 102:266–269.

    Google Scholar 

  • Rusnak MG (1995) Biotechnology of diagnostics: Emerging opportunities. Bio/Technol 13:1056–1058.

    Google Scholar 

  • Schwartz C (1975) The corporate connection. Bull Atom Sci 31:15–19.

    Google Scholar 

  • Schwartz C (1980) Scholars for dollars. In: Arditti R, Brennan P, Cavrak S (eds) Science and Liberation. Boston: South End Press, pp 171–190.

    Google Scholar 

  • Sheen MR (1992) Barriers to scientific and technical knowledge acquisition in industrial R&D. R&D Mgmt 22:135–143.

    Google Scholar 

  • Spalding BJ (1994) Roche and SKB sink big bucks into genomics. Bio/Technol 12:559–560.

    Google Scholar 

  • Stipp D (1993) IG labs quietly breaks new ground in biotechnology: Advances in genetic testing raise lucrative, and thorny, possibilities. Wall Street Journal June 14, p B3.

  • Stone R (1995) Rockefeller strikes fat deal with Amgen. Science 268:631.

    Google Scholar 

  • Trigg ME, Geier MR (1992) On the relationship between academic and private genetic services. Am J Hum Genet 51:890–891.

    Google Scholar 

  • Ward BE, Gersen SL, Klinger KW (1992) A rapid (but wrong) prenatal diagnosis: Integrated genetics replies. N Engl J Med 326:1639–1640.

    Google Scholar 

  • Warren RJ (1992) Survival of academic-based genetic laboratory services. Am J Hum Genet 51:892–893.

    Google Scholar 

  • Watson JD (1990) The Human Genome Project: Past, present and future. Science 248:44–49.

    Google Scholar 

  • Weiner C (1989) Patenting and academic research: Historical case studies. In: Well V, Snapper J (eds) Owning Scientific and Technical Information Value and Ethics Issues. New Jersey: Rutgers University Press, pp 99–103.

    Google Scholar 

  • Witt MD, Gostin LO (1994) Conflict of interest dilemmas in biomedical research. J Am Med Assoc 271:547–551.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Genetics, The Shriver Center for Mental Retardation, Waltham, Massachusetts (MRN and CA);

    Marvin R. Natowicz & Catherine Ard

  2. The Departments of Neurology, Pathology and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts (MRN);

    Marvin R. Natowicz & Catherine Ard

  3. The Florence Heller Graduate School for Advanced Studies in Social Welfare, Brandeis University, Waltham, Massachusetts (CA).

    Marvin R. Natowicz & Catherine Ard

Authors
  1. Marvin R. Natowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Ard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Natowicz, M.R., Ard, C. The Commercialization of Clinical Genetics: An Analysis of Interrelations Between Academic Centers and For-Profit Clinical Genetics Diagnostics Companies. Journal of Genetic Counseling 6, 337–355 (1997). https://doi.org/10.1023/A:1025632423186

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025632423186

Search

Navigation